{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:09:25Z","timestamp":1780805365105,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1124\/dmd.118.082065","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T14:03:06Z","timestamp":1531231386000},"page":"1384-1389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis"],"prefix":"10.1016","volume":"46","author":[{"given":"Birgit M.","family":"Wollmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje Watterdal","family":"Syversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vistnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise L.","family":"Mehus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.082065_bib1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0026-895X(25)13247-1","article-title":"Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture","volume":"44","author":"Abdel-Razzak","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.118.082065_bib2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082065_bib3","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1124\/dmd.118.082065_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1359-6101(02)00020-5","article-title":"The balance between IL-1 and IL-1Ra in disease","volume":"13","author":"Arend","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1124\/dmd.118.082065_bib5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1124\/dmd.113.051136","article-title":"Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4\u03b2-hydroxycholesterol in a high-dose vitamin D supplementation study","volume":"41","author":"Bj\u00f6rkhem-Bergman","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082065_bib6","doi-asserted-by":"crossref","first-page":"31534","DOI":"10.1074\/jbc.M201712200","article-title":"Metabolism of 4\u03b2-hydroxycholesterol in humans","volume":"277","author":"Bodin","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.118.082065_bib7","doi-asserted-by":"crossref","first-page":"38685","DOI":"10.1074\/jbc.M105127200","article-title":"Antiepileptic drugs increase plasma levels of 4\u03b2-hydroxycholesterol in humans: evidence for involvement of cytochrome P450 3A4","volume":"276","author":"Bodin","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.118.082065_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2012.00008","article-title":"Immunological response as a source to variability in drug metabolism and transport","volume":"3","author":"Christensen","year":"2012","journal-title":"Front Pharmacol"},{"key":"10.1124\/dmd.118.082065_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.apha.2015.03.005","article-title":"Role of cytochrome P450s in inflammation","volume":"74","author":"Christmas","year":"2015","journal-title":"Adv Pharmacol"},{"key":"10.1124\/dmd.118.082065_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2172-10-52","article-title":"Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays","volume":"10","author":"de Jager","year":"2009","journal-title":"BMC Immunol"},{"key":"10.1124\/dmd.118.082065_bib11","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.111.038679","article-title":"Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture","volume":"39","author":"Dickmann","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082065_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/FPC.0b013e3282f50ee9","article-title":"4\u03b2-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians","volume":"18","author":"Diczfalusy","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.118.082065_bib13","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1111\/bcp.13341","article-title":"4\u03b2-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients","volume":"83","author":"Gjestad","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.082065_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bcp.12833","article-title":"4\u03b2-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?","volume":"81","author":"Gjestad","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.082065_bib15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clpt.2004.11.112","article-title":"Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo","volume":"77","author":"He","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.082065_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00228-016-2178-y","article-title":"Impact of genetic and nongenetic factors on interindividual variability in 4\u03b2-hydroxycholesterol concentration","volume":"73","author":"Hole","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.118.082065_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00228-008-0492-8","article-title":"CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4\u03b2-hydroxycholesterol levels","volume":"64","author":"Josephson","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.118.082065_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2013.00012","article-title":"Pharmacogenomics of cytochrome P450 3A4: recent progress toward the \u201cmissing heritability\u201d problem","volume":"4","author":"Klein","year":"2013","journal-title":"Front Genet"},{"key":"10.1124\/dmd.118.082065_bib19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2125.2000.00314.x","article-title":"Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis","volume":"50","author":"Mayo","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.082065_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/dmd.118.082065_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.dmpk.2014.09.004","article-title":"Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4","volume":"30","author":"Mimura","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.118.082065_bib22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00228-011-1163-8","article-title":"Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation","volume":"68","author":"Molanaei","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.118.082065_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/dmd.107.018747","article-title":"Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer","volume":"36","author":"Morgan","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082065_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1124\/dmd.118.082065_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/17425255.1.4.629","article-title":"Regulation of drug metabolism and disposition during inflammation and infection","volume":"1","author":"Renton","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.118.082065_bib26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjc.6600448","article-title":"Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response","volume":"87","author":"Rivory","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.118.082065_bib27","doi-asserted-by":"crossref","unstructured":"Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S (2011) Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis [published correction appears in Clin Pharmacol Ther 2011;90:479]. Clin Pharmacol Ther 89:735\u2013740.","DOI":"10.1038\/clpt.2011.35"},{"key":"10.1124\/dmd.118.082065_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jim.2008.04.006","article-title":"Effects of blood sample handling procedures on measurable inflammatory markers in plasma, serum and dried blood spot samples","volume":"336","author":"Skogstrand","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1124\/dmd.118.082065_bib29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/dmd.32.3.359","article-title":"Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes","volume":"32","author":"Sunman","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.082065_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00628.x","article-title":"Th17 cells in human disease","volume":"223","author":"Tesmer","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1124\/dmd.118.082065_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/clpt.2012.261","article-title":"Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects","volume":"93","author":"Ulvestad","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.082065_bib32","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/bcp.13083","article-title":"Comparative performance of oral midazolam clearance and plasma 4\u03b2-hydroxycholesterol to explain interindividual variability in tacrolimus clearance","volume":"82","author":"Vanhove","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.082065_bib33","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.118.082065_bib34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/cts.12431","article-title":"4\u03b2-hydroxycholesterol level in patients with rheumatoid arthritis before vs. after initiation of bDMARDs and correlation with inflammatory state","volume":"10","author":"Wollmann","year":"2017","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.118.082065_bib35","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jcph.561","article-title":"Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach","volume":"55","author":"Zhuang","year":"2015","journal-title":"J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624056010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624056010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.082065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:37:29Z","timestamp":1739903849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624056010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0090955624056010"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.082065","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.082065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}